- Home
- TXG vs DNTH Comparison
TXG vs DNTH Comparison
Compare TXG & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TXG | DNTH |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.9B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | TXG | DNTH |
|---|---|---|
| Price | $17.77 | $44.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 10 |
| Target Price | $14.73 | ★ $68.00 |
| AVG Volume (30 Days) | ★ 3.3M | 780.0K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $641,814,000.00 | $3,078,000.00 |
| Revenue This Year | $4.50 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.92 | N/A |
| 52 Week Low | $6.78 | $13.37 |
| 52 Week High | $20.34 | $45.46 |
Technical Indicators
Market Signals| Indicator | TXG | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 57.17 | 65.78 |
| Support Level | $17.06 | $42.00 |
| Resistance Level | $19.29 | $45.46 |
| Average True Range (ATR) | 1.08 | 2.00 |
| MACD | -0.10 | 0.13 |
| Stochastic Oscillator | 48.84 | 79.49 |
Price Performance
Historical ComparisonAbout TXG 10x Genomics Inc.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.